Anti-inflammatory-antioxidant modifications and synbiotics improved health-related conditions in patients with progressive forms of multiple sclerosis: A single-center, randomized clinical trial.

Moravejolahkami, Amir Reza; Chitsaz, Ahmad; Hassanzadeh, Akbar; Paknahad, Zamzam

Moravejolahkami, Amir Reza; Chitsaz, Ahmad; Hassanzadeh, Akbar; Paknahad, Zamzam.

Afiliação

Moravejolahkami AR; Department of Clinical Nutrition, School of Nutrition & Food Science, Isfahan University of Medical Sciences, Isfahan, Iran. Electronic address: moravejolahkami@gmail.com.
Chitsaz A; Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran. Electronic address: chitsaz@med.mui.ac.ir.
Hassanzadeh A; Department of Epidemiology and Biostatistics, School of Health, Isfahan University of Medical Sciences, Isfahan, Iran. Electronic address: hassanzadeh.aja@gmail.com.
Paknahad Z; Department of Clinical Nutrition, School of Nutrition & Food Science, Isfahan University of Medical Sciences, Isfahan, Iran. Electronic address: paknahad@hlth.mui.ac.ir.

Complement Ther Clin Pract ; 53: 101794, 2023 Nov.

Article em En | MEDLINE | ID: mdl-37651846

Assuntos

Esclerose Múltipla Crônica Progressiva; Esclerose Múltipla; Simbióticos; Humanos; Esclerose Múltipla/terapia; Antioxidantes/uso terapêutico; Método Simples-Cego; Esclerose Múltipla Crônica Progressiva/tratamento farmacológico; Dor; Fadiga/etiologia; Fadiga/terapia; Método Duplo-Cego

Palavras-chave

Anti-inflammatory agents; Fatigue; Pain; Progressive multiple sclerosis; Randomized controlled trial; Synbiotics

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Esclerose Múltipla Crônica Progressiva / Simbióticos / Esclerose Múltipla Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google